Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: XBIO
1 year chart
1 day chart
Xenetic Biosciences
www.xeneticbio.com/default.aspx

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications.

Xenetic drug development operation to be re-located to Massachusetts

14th Jun 2012, 3:20 am by Ian Lyall

 

Xenetic Biosciences (LON:XEN) this morning announced it is relocating its drug development operations to Massachusetts.

Currently the group, which is working on treatments for rare and orphan diseases, carries out in-house optimisation and pre-clinical work at its own laboratories here in the UK.

The decision to head to one of the world’s preeminent biotechnology hubs follows a March 2011 visit to Britain by a delegation from industry and academia led by state governor Deval Patrick, Xenetic revealed. 

The company will hire up to six employees in Massachusetts before the end of the year and has plans to have increased this to 20 within 12 months of that date.

Chief executive Scott Maguire, a native of Boston, said: "Committing our company's entire drug development operations to Massachusetts is certainly a bold step but is surely one which presents an excellent opportunity to prove ourselves as a leading technology provider in the quest to develop better drug therapies which address areas of unmet need and confer genuine advantage to both patients and providers.  

“We have worked closely with the Patrick Administration as we made this decision, and I have every confidence that the team in Massachusetts will be working with us every step of the way to maximize the likelihood of this being another great success for the Massachusetts supercluster."

Xentic’s three leading drug candidates are PolyXen, which extends the efficacy of biologic drugs, OncoHist, which is a potential breakthrough cancer treatment, and ImuXen, for creating and improving vaccines.

 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here